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Methodology for AACT Evidence-based Recommendations on the use 
of Intravenous Lipid Emulsion Therapy in poisoning  
 
Abstract 
Intravenous lipid emulsion (ILE) therapy is a novel treatment that was discovered in the 
last decade. Despite unclear understanding of its mechanisms of action, numerous and 
diverse publications attested to its clinical use. However, current evidence supporting its 
use is unclear and recommendations are inconsistent. To assist clinicians in decision-
making, the American Academy of Clinical Toxicology created a workgroup composed of 
international experts from various clinical specialties, which includes representatives of 
major clinical toxicology associations. Rigorous methodology using the AGREE II 
instrument was developed to provide a framework for the systematic reviews for this 
project and to formulate evidence-based recommendations on the use of ILE in 
poisoning. Systematic reviews on the efficacy of ILE in local anesthetic toxicity and non-
local anesthetic poisonings as well as adverse effects of ILE are planned. A 
comprehensive review of lipid analytical interferences and a survey of ILE costs will be 
developed. The evidence will be appraised using the GRADE system. A thorough and 
transparent process for consensus statements will be performed to provide 
recommendations, using a modified Delphi method with two rounds of voting.  This 
process will allow for the production of useful practice recommendations for this 
therapy. 
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Introduction 
Local anesthetic systemic toxicity (LAST) is a potentially severe iatrogenic occurrence 
with an estimated incidence of approximately 1 per 1000 procedures. The clinical 
presentation ranges from seizures and dysrhythmias to cardiac arrest.  Treatment 
consisting of oxygenation, ventilation, atropine and standard cardiac resuscitation, is 
often ineffective (1). Overdoses with lipid-soluble substances, such as antidepressants 
and cardiac medications, rank 5th and 6th in the list of most common substance 
categories reported to the US National Poison Data System (2). Although the fatality rate 
from the data available remains imprecise, neurotoxicity and cardiovascular toxicity 
associated with lipid soluble substances may be severe and significant morbidity is 
common. 
 
A brief historical review of the use of intravenous lipid emulsion (ILE) in medical 
toxicology starts in 1997, when an in-vivo animal model of bupivacaine toxicity showed 
that in the presence of ILE the amount of bupivacaine required to induce LAST was 
significantly increased (3). It is almost a decade later, in 2006, that the first human case 
of LAST successfully treated with ILE therapy was reported (4). In 2008, with the 
hypothesis that other lipid soluble drugs might also be influenced by this treatment, ILE 
was used in a patient with oral bupropion and lamotrigine toxicity after standard 
toxicology resuscitation was failing, with subsequent survival (5). Since the publication 
of this case report, ILE has been increasingly employed in anesthesia and medical 
toxicology (4, 5).  The American College of Medical Toxicology published an interim 
guidance statement regarding its use in 2011 (6). Despite many reviews published in 
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recent years, the literature is dominated by animal models with unclear generalizability 
to humans, numerous opinion articles, and anecdotal case reports of variable quality  
and highly prone to publication bias (7-9). 
 
Previously, ILE was primarily used for parenteral nutrition, drug transport or chemo-
embolization. Currently, they have become part of the treatment options available to 
anesthesiologists, intensivists, emergency physicians, and medical toxicologists in the 
treatment of poisoning. Although the mechanisms of actions are still not entirely clear, 
three main hypotheses have been proposed: sequestration of the offending xenobiotic in 
an expanded plasma lipid phase (the “lipid sink” theory), alteration in ionic channel 
permeability (activation of voltage-gated calcium or sodium channels) and modification 
of fatty acid utilization by the poisoned myocardium (the “bioenergetics” theory)(10).  
 
The present workgroup was established by the American Academy of Clinical Toxicology 
to produce evidence-based recommendations on the use of ILE in poisoning to aid 
clinicians in their decision-making in urgent situations. Recommendations are intended 
to rely on the best available data, although few controlled studies have been conducted 
on the use of ILE in humans.  The non-standardized protocols used for ILE result in 
significant variability in management, both in amount of ILE given as well as in duration 
of treatment. The rapid clinical improvements reported in some published case reports 
have therefore fostered an enthusiasm for this new therapy, especially for patients who 
fail to respond to other treatments. Frequently, the dose and duration of ILE for 
treatment of lipophilic drug toxicity exceed the maximum accepted dosage used in the 
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parenteral nutrition literature. Potential adverse effects and costs have neither been 
well studied nor reported.   
 
There are numerous factors that create variability, and therefore pose difficulties in 
comparing studies.  These factors include the large number of xenobiotics for which this 
therapy has been tried, inconsistencies in the amount, duration and constitution of ILE 
used, and the differences between oral poisoning and LAST, which is more often 
parenteral. Nevertheless, this workgroup has elected to proceed with the systematic 
identification, review and critique of all available evidence using the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) approach(11). 
Because human case reports may reveal important information about toxicokinetics, 
and because there appears to be a temporal relationship between ILE administration 
and clinical improvement, this workgroup has opted to include case reports.    
 
With the anticipated low quality evidence, the term ”guidelines” might not be 
appropriate for this endeavor. Nevertheless, because of the use of the Appraisal 
of Guidelines for Research and Evaluation (AGREE) II instrument (Appendix 1 available 
on-line at: insert URL here), the results are based on a rigorous process of synthesis and 
methodology, which under the circumstances adds value to the current debate (12).  The 
workgroup has therefore chosen the wording "Recommendations", which will reflect the 
best available evidence at the time of publication. 
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Objectives of the workgroup 
Our objectives are to summarize the available evidence on: 1) the clinical efficacy of ILE 
with non-local anesthetic poisoning; 2) the clinical efficacy of ILE with local anesthetic 
poisoning; and 3) the adverse effects of ILE divided into clinical effects and analytical 
interference. To fulfill these objectives, three systematic reviews and a comprehensive 
review on analytical interferences from ILE will be performed. Based on the evidence 
collected and the results of these systematic and comprehensive reviews, 
recommendations on the use of ILE in the context of poisoning will be developed. The 
clinical efficacy of ILE will be measured against current standards of care and alternative 
treatments, and balanced with its potential complications and costs.  
 
Methodology  
Group selection  
At least two representatives from national and international medical toxicology 
associations have been delegated by their respective boards to serve on this workgroup. 
The number of representatives was selected according to the size of the associations’ 
membership. In order to ensure that the workgroup was fully representative, and 
included different specialty stakeholders with the expertise needed to assess every 
aspect of this therapy, additional experts were recruited based on recommendations 
from various societies or on their particular clinical expertise.  One participant was 
chosen because of expertise in epidemiology and guideline methodology, but will not 
participate in the voting of the recommendations. Two medical librarians were included 
in the workgroup to design and conduct systematic searches of the literature and to 
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assist with article retrieval but were not voting members. Medical biochemists and non-
clinician pharmacists will be excluded from voting, but will participate in assessing the 
quality of the data for the adverse effects profile of ILE. Participants divulged all 
potential conflicts of interests prior to inclusion in the workgroup (Table 1) and the final 
selection was done to avoid conflict of interest (financial, academic or others) to respect 
the Institute of Medicine most recent recommendations. (13) 
 
The first meeting of the workgroup took place in Atlanta, Georgia, USA on September 
29th 2013. The majority of the members at the time were present either in person or by 
telephone (N=16/24); one non-voting workgroup member was added after the meeting. 
The purpose of this meeting was to establish the methodology structure, and agree on a 
timeline and work division in order to produce recommendations that will be both 
rigorous and transparent. Decisions on methodology were based on majority votes 
(50% + 1). 
 
Criteria for publication inclusion  
Type of Participants 
The studied participants for the evaluation of the efficacy of ILE will be patients or 
animals to whom ILE was given. There will be no restriction on the context of the 
poisoning (acute or chronic), on the poison or on the heterogeneity of the participants 
(e.g. special populations such as pediatric, chronic kidney disease, hepatic insufficiency, 
pregnancy). Studied participants for the search regarding adverse effects of ILE will 
include patients who received ILE either in for poisoning or for other indications. 
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Type of Interventions 
ILE will be considered as the intervention of interest for the efficacy evaluation only if 
instituted, at least partially, for the purpose of treating poisoning. Studies in which ILE 
was instituted for other indications will be excluded. Any administration of ILE therapy 
(poisonings or total parental nutrition) will be reviewed to estimate the risk of adverse 
events. 
 
Type of comparisons 
Clinical efficacy of ILE versus other resuscitative therapies will be reviewed. When 
applicable, different formulations, dosages and durations of ILE will be compared for 
efficacy or adverse events. 
 
Type of outcomes 
The primary outcome of interest is survival. Secondary outcomes, seizure duration, time 
to resolution of cardiac dysrhythmias, time and achievement of hemodynamic 
endpoints, (blood pressure, heart rate), neurological recovery (altered mental status, 
coma), and potential adverse events (pancreatitis, fat emboli, etc.) associated with ILE 
will also be evaluated. 
 
Type of studies 
Study designs that will be considered for inclusion in the systematic reviews are: 
randomized controlled trials, non-randomized controlled trials, observational studies, 
case series/ case reports, abstracts from clinical toxicology meetings (from 2000 
onwards), abstracts from other specialties (from 2010 onwards), and animal studies for 
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the different systematic reviews. For the comprehensive review addressing analytical 
interferences due to ILE, reports of method and instrument evaluations published in 
peer-reviewed journals will be appraised. Additionally, abstracts from representative 
clinical toxicology meetings and clinical chemistry meetings from 2009 onwards as well 
as package inserts from widely used and situationally-relevant assay methodologies will 
be included for consideration. 
 
Publication selection 
Search Strategy 
Two medical librarians (MM, AMN) will identify candidate studies for this review by 
conducting three searches.  The first will be a systematic search on ILE in toxicology for 
the treatment both of local anesthetic toxicity and non-local anesthetic toxicity; results 
from this search thus will provide the basis for two of the three systematic reviews to be 
produced by this workgroup. The second will be a systematic search on adverse effects 
of ILE and parenteral nutrition. The third search on lipid laboratory interferences will be 
conducted in order to provide supporting evidence during the analysis of the third 
systematic review, and will be thus comprehensive rather than systematic. 
 
For each search, we will use a search strategy for Medline (via Ovid) that will be adapted 
to Embase (via Ovid), CINAHL (via EBSCO), BIOSIS Previews (via Ovid), Web of Science, 
Scopus and the Cochrane Library/DARE, with an inception date of December 15th 2014 
(Appendices 2 to 4 available on-line at: insert URL here). 
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The Medline search strategies will comprise a combination of Medical Subject Headings 
(MeSH), title/abstract key words, truncations and Boolean operators and are given in 
full in Appendices 2 to 4 (available on-line at: insert URL here). The first search will 
include the concepts of ILE and toxicology (including but not limited to calcium channel 
blockers, beta blockers and sodium channel blockers).  The second search will include 
the concepts of ILE and parenteral nutrition, combined with the BMJ Clinical Evidence 
Adverse Effects filter (BMJ Clinical Evidence, 2012).  
 
In addition, conference abstracts from the European Association for Poison Centres and 
Clinical Toxicologists, and the North American Congress of Clinical Toxicology (both 
from 2000–2014) and previous reviews will be hand-searched by various group 
members.  Abstract from the Asia Pacific Association of Medical Toxicology will be 
searched from 2007 to 2014. Group members will perform cross-referencing of full-text 
articles.  No limits will be applied for language and candidate studies in languages not 
known to any of the authors will be translated. 
 
Publication exclusion 
The workgroup will consider any original peer-reviewed article or abstract published in 
a peer-reviewed journal. Reviews, editorials, book chapters, and commentaries will be 
included only if they contained original data.  Studies which after full text review will be 
found not to contain enough data will be excluded. Animal studies will be excluded if the 
methods and results are uninterpretable or cannot be extrapolated to humans. 
Publications describing the use of ILE solely for the treatment of nutritional needs will 
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be excluded from the efficacy systematic review, but will be included in the adverse 
effect systematic review. Pre-treatment studies and experimental in-vitro or ex-vivo 
models will be excluded due to their inability to be generalizable to the context of 
human poisoning. 
 
Reporting by subgroup 
The workgroup will be divided into subgroups, each of which will be responsible for 
reviewing a different aspect of the therapy. A summary of the search strategy will be 
described in their distinct manuscript for each systematic review by the responsible 
subgroup and the librarians, according to the PRISMA statement (14). It will describe in 
detail the number of references retrieved in the initial search. The number of duplicates 
and excluded publications will be stated, with the reason for exclusion (relevance, very 
poor quality, publication type). Any disagreement in the exclusion process will be 
addressed explicitly. 
 
Poison selection 
All poisons for which ILE will be reported as a treatment for acute or chronic toxicity 
will be included for the systematic review. Poisons for which the group will determine 
that sufficient cases have been reported (more than 3 subjects) will be evaluated 
through the voting process, which is to occur at a later date. 
 
Data extraction, synthesis, presentation and interpretation 
Data extraction 
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For each publication retained in each different database, the responsible subgroup will 
extract all relevant data into a standardized data extraction document. Relevant data 
that will be extracted will include : demographic information, description of poisoning 
(amount of poison, timing, administration route, coingestion), severity of poisoning 
(poison specific clinical symptoms, signs and relevant laboratory analyses), ILE 
administered (lipid formulation and concentration, use of a bolus (amount and timing of 
administration), use of an infusion (rate and duration) and total amount of lipid received 
converted in g/kg), concomitant treatments (type, dose and duration), clinical outcomes 
(general and specific to the described poisoning), adverse effects of therapy (type, 
severity and timing) and duration of follow-up. At this stage, no calculation, inference or 
interpretation will be attempted. All publications likely to be excluded (according to the 
previous criteria) will be marked for re-evaluation by the expert subgroup. To reduce 
the risk of errors, two independent reviewers will evaluate each publication. To ensure 
uniformity, the group leader will merge individual data extraction flow sheets. If 
observational studies or randomized controlled trials are included, the epidemiologist 
will assist the evaluation of the quantitative measure of effect and quality of evidence for 
clinical outcomes.  
 
Evaluation of extracted data 
For each publication included in the specific poison database, the subgroup will first 
evaluate publications marked for exclusion. A publication will be rejected only if all 
members of the subgroup agree. If there is strong disagreement on the inclusion or 
exclusion of a determined publication, the chair will adjudicate. When the final 
summaries will be presented to the workgroup for the recommendations assessment, 
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the arguments for and against inclusion of a particular publication will also be presented 
for transparency. Each individual publication will be assessed in regards to its quality 
for clinical outcomes or adverse effects accordingly with recognized reporting guidelines 
(15-20). The final level of evidence will be reported as per the GRADE system 
(methodological biases, indirectness, imprecision, and error) (11, 21). Also, the effect of 
ILE will be reported for each clinical outcome (descriptive value and/or comparative 
values, such as risk difference, relative risk or p-value, if applicable). Because of the 
controversy as to which kinetic outcome (free drug concentration or apparent half-life 
changes) is valid to appraise success of ILE, they will only be reported if measured. 
 
Data Synthesis 
Following the previous steps, the subgroup will create a summary sheet. Data will be 
regrouped to allow synthesis principally by poison or group of poisons, and if feasible, 
by intervention and by sub-population. The quality of the evidence will be summarized 
for each outcome (Appendix 5 available on-line at: insert URL here). The effect of ILE 
and risk of adverse effects will be summarized qualitatively or quantitatively for each 
outcome. For the review of analytical interferences, the data will be grouped by analyte 
and/or methodology. Any general comments on the reviewed literature will be added to 
the summary sheet. The definitions and terminology used is presented in Table 2. 
 
Lipid emulsion costs 
A survey will be distributed internationally to pharmacists of health care agencies and 
health care organizations to assess the acquisition costs and patient charges for different 
ILE formulations and comparative treatments available in their countries. This is not 
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intended to provide a rigorous cost analysis study or to assess cost-effectiveness of ILE. 
Rather, it will give an overall idea of the monetary costs associated with administration 
of various ILE formulations, their adequate storage and expiry date required for 
availability.  
 
Recommendations on the use of ILE 
Statement proposal 
After reviewing and summarizing the available literature, the subgroup will propose a 
series of statements concerning the use of ILE in poisoning. These statements will take 
into account the quality of evidence, the relative importance of the outcomes, expected 
clinical course without ILE, the availability of other therapies, the magnitude and the 
precision of the effect, the balance between benefits and harms and the costs of the 
procedure. 
 
Prototype Statements 
1) General statement: (we recommend/ we suggest/ neutral position/ no agreement 
reached) to (give/ not give) ILE in poisoning with "X". 
2) Specific statements: If there is support, other statements will be submitted: 
indications for initiating ILE (ingestion dose, drug concentration, special population, 
symptoms, clinical markers), type of ILE regimen (dose, duration, rate and formulation 
of ILE), and any other statement particular to the poison deemed significant by the 
subgroup (e.g. alternative therapy, antidote). 
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The subgroup will submit the following documents to the workgroup: complete 
publications, merged flow sheet, summary sheet and the proposed voting statements. At 
any step throughout the process, if there is strong disagreement or dissent, the issues 
will be brought to the entire workgroup for review.  
 
Voting procedure  
Since much of the literature reviewed is likely to be of low methodological quality, the 
majority of recommendations will be based on a consensus of expert opinions. 
Therefore, a rigorous voting procedure will be implemented to ensure transparency and 
reproducibility. The modified Delphi method (i.e., an iterative consultation of experts on 
a given subject) was chosen to reach a formal consensus on proposed voting statements. 
Two rounds of consultation are scheduled before the final version is submitted. 
 
For the first round, the subgroup will submit statements to each workgroup member 
who anonymously will indicate their level of agreement and include comments. 
Approval for the proposed statement will be recorded on a 9-point Likert scale (with 1 
being completely against and 9 being completely for the proposed statement). Every 
member will be encouraged to expand on or challenge proposed statements. 
 
After completion of the first round, votes and comments will be summarized. The 
RAND/UCLA Appropriateness Method (a method of statistical measurement frequently 
used and adapted to all panel sizes) will be used to quantify the votes (22). The median 
values and the lower/upper quartiles will be reported and the disagreement indexes 
calculated. Median values ranging from 7-9 will reflect that the workgroup is in favor of 
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the proposed statement, 4-6 will reflect a neutral position and 1-3 will reflect that the 
workgroup is not in favor of the statement. The disagreement index, defined as the 
interpercentile range divided by the interpercentile range adjusted for symmetry, 
describes the dispersion of ratings more effectively than the mean absolute deviation 
from the median. Index values less than or equal to 1 will indicate agreement (23). 
 
A standardized form will then be resubmitted to each participant with his or her vote, 
summary statistics, and workgroup comments and modified statements. The second 
voting round will take place after a meeting where the results of the first round of the 
votes will be discussed in a face-to-face meeting for the majority of the workgroup 
members and others joining by teleconferencing. All subgroups will present the 
evidence a second time i.e. potential risks, costs, alternative treatments, clinical benefit, 
for every reviewed poison. After this presentation, the workgroup will take time to 
deliberate these findings. Each statement will then be re-voted privately and 
anonymously. 
 
 The voting procedure will result in providing strength of recommendations (see Figure 
1). Because of the restricted number of experts voting, if dissent remains, the final 
decision and debate will be explained in the official recommendation document for 
transparency. Interpretation of each level of strength of recommendation is explained 
on Table 3. 
 
Values and preferences 
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Values and preferences of the patients will not be evaluated as part of this work (after 
discussion with a representative of the AGREE consortium) since this is not a 
homogenous population. The clinical situations evaluated being in a resuscitative 
context pose inherent limitations to the timeliness of decision-making by clinicians and 
the ability of patients to evaluate their own risk-benefit considerations. However, values 
and preferences susceptible to influence the votes of the stakeholders will be evaluated 
at the end of the process by a survey conducted by the methodologist. 
 
Writing and review process 
The Board of Trustee of the American Academic of Clinical Toxicology (AACT), as the 
main sponsoring organization, has first endorsed this methodology manuscript, while 
other participating organizations provided comments through their representatives. 
Four distinct manuscripts will be prepared for the evidence reviews and will be 
submitted through standard peer-reviewed publication process. No supplementary 
review or endorsement will be required by AACT for these scientific reviews.  The last 
manuscript which is to include the recommendations will be submitted to AACT and 
other participating organizations for endorsement prior to publication. 
 
 
Implementation and applicability 
Following endorsement by AACT and publication of the recommendations, these 
recommendations will be available on AACT website for dissemination. Members of the 
workgroup intend to conduct an international survey of end-user clinicians to identify 
the impact of the recommendations on their practice.  
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Updating 
These recommendations will be updated if there is a significant change in the evidence, 
at the request of AACT or no later than 5 years after publication. A search strategy will 
be registered in different search engines for updates.  
 
Conclusion 
Intravenous lipid emulsion therapy for poisoning is a recent development in medical 
toxicology. The heterogeneity of the literature warrants a thorough review and appraisal 
of the evidence. Rigorous methodology combined with a transparent recommendations 
process development will assist clinicians in making choices when treating patients with 
substances potentially amenable to treatment with intravenous lipid emulsion therapy. 
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